<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="style.css">
    <title>Antigenic Characterisation of Alphaviruses - Research Poster</title>
</head>

<body>
    <!-- Navigation Bar -->
    <nav class="navbar">
        <div class="nav-left">
            <span class="logo">SCIE3121</span>
        </div>
        <button class="menu-toggle" id="menuToggle">
            <span></span>
            <span></span>
            <span></span>
        </button>
        <ul class="nav-links" id="navLinks">
            <li><a href="#home" class="nav-item">Poster</a></li>
            <li><a href="#background-section" class="nav-item">Background</a></li>
            <li><a href="#methods-section" class="nav-item">Methods</a></li>
            <li><a href="#results-section" class="nav-item">Results & Key Findings</a></li>
            <li><a href="#future-section" class="nav-item">Future Directions</a></li>
        </ul>
    </nav>

    <!-- Hero Section - Poster Title -->
    <section class="hero_section" id="home">
        <div class="section_container">
            <div class="hero_container">
                <div class="text_section">
                    <h1>Antigenic Characterisation of Pathogenic and Chimeric Alphaviruses Using a Novel Insect-Specific Platform</h1>
                    <p class="subtitle">Research Project | SCIE3121</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Main Poster Content -->
    <section class="poster_content" id="poster">
        <div class="section_container">
            <!-- Research Highlights Grid -->
            <div class="poster_grid">
                <!-- Background -->
                    <div class="poster_card">
                        <h3>Background</h3>
                        <p>Alphaviruses such as Chikungunya cause widespread outbreaks and are under‑detected due to misdiagnosis and limited laboratory access; an insect‑specific platform enables safe antigenic study in this context.</p>
                    </div>

                    <!-- Aims -->
                    <div class="poster_card">
                        <h3>Aims</h3>
                        <p>Evaluate 11F4 as a potential pan‑alphavirus antibody and characterise antigenic differences between pathogenic and chimeric alphavirus constructs.</p>
                    </div>

                    <!-- Methods -->
                    <div class="poster_card">
                        <h3>Methods</h3>
                        <p>Chimeric constructs were generated by CPER and expressed in insect cells; antigen expression and antibody binding were assessed by ELISA, SDS‑PAGE and neutralisation assays.</p>
                    </div>

                    <!-- Key Findings -->
                    <div class="poster_card">
                        <h3>Key Findings</h3>
                        <p>Preliminary results show distinct antigenic signatures between pathogenic and chimeric constructs, and indicate the platform is a safer, scalable system for vaccine research.</p>
                    </div>
                    </div>
            </div>
        </div>
    </section>

    <!-- Background Section -->
    <section class="detail_section" id="background-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Background</h2>

                <div class="content_section">
                    <h3>Alphaviruses</h3>
                    <p>Alphaviruses, including Chikungunya virus (CHIKV), Ross River virus (RRV), and equine encephalitis viruses, cause large outbreaks across Central and East Africa, Southeast Asia, and South America. CHIKV transmission has been reported in over 100 countries with an estimated 35 million infections annually; frequent misdiagnosis with pathogens such as dengue or influenza and limited access to confirmatory laboratory testing have constrained surveillance and vaccine development in endemic regions.</p>

                    <p>Alphaviruses are small, enveloped RNA viruses with a positive-sense, single-stranded genome transmitted by blood-feeding vectors (most commonly mosquitoes). They cause acute febrile illness, arthralgia, and, in some cases, encephalitis. Definitive diagnosis often requires laboratory methods such as RT‑PCR, highlighting the need for accessible, affordable rapid diagnostics in low-resource settings.</p>
                </div>

                <div class="content_section">
                    <h3>Insect-Specific Viruses (ISVs)</h3>
                    <p>Advances in next-generation sequencing and metagenomic surveillance have identified diverse insect-specific viruses (ISVs) that do not replicate in vertebrate cells. While early ISV work concentrated on flaviviruses, recent studies report insect-specific alphaviruses (ISAs) such as <strong>Yada Yada Virus (YYV)</strong> and <strong>Eilat Virus (EILV)</strong>, which form a clade restricted to insect hosts.</p>
                </div>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    <p>Viral antigens are critical for immune recognition and vaccine development. Key antigenic components include:</p>
                    <ul>
                        <li><strong>Envelope Proteins (E1 and E2):</strong> Primary targets for neutralising antibodies</li>
                        <li><strong>Non-structural Proteins (nsP1-nsP4):</strong> Involved in viral replication and immune evasion</li>
                        <li><strong>Capsid Protein:</strong> Structural antigen recognised in some immune responses</li>
                    </ul>
                    <p>Antigenic variation between strains influences viral pathogenesis, transmissibility, and vaccine efficacy.</p>
                </div>

                <div class="content_section">
                    <h3>Vaccine Development Challenges</h3>
                    <p>Despite their public health importance, no approved vaccines exist for most alphaviruses. Key challenges include:</p>
                    <ul>
                        <li>Understanding precise antigenic epitopes for vaccine design</li>
                        <li>Balancing immunogenicity with safety</li>
                        <li>Managing antigenic drift and population heterogeneity</li>
                        <li>Cost-effective production platforms</li>
                    </ul>
                </div>

                <div class="content_section">
                    <div class="highlight_box">
                        <h4>Project Aims:</h4>
                        <p>1) Evaluate the potential of 11F4 as a pan-alphavirus antibody.<br>2) Antigenic characterisation of chimeric alphaviruses.</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Insect-Specific Viruses as Platforms</h3>
                    <p> 
                    Previous studies have extensively explored the use of insect-specific flaviviruses.
                    </p>
                </div>
            </div>
        </div>
    </section>

    <!-- Methods Section -->
    <section class="detail_section" id="methods-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Methods & Insect-Specific Platform</h2>

                <div class="content_section">
                    <h3>Overview of the Insect-Specific Platform</h3>
                    <p>The insect-specific platform represents a paradigm shift in research methodology for pathogenic alphaviruses. This innovative approach leverages insect-specific viruses as the backbone for expressing alphavirus antigenic components, providing a safe, manageable system for detailed characterisation.</p>
                    
                    <div class="highlight_box">
                        <h4>Platform Advantages:</h4>
                        <p>• <strong>Biosafety:</strong> Limited replication in mammalian cells<br>
                        • <strong>Scalability:</strong> Easy production in insect cell culture<br>
                        • <strong>Flexibility:</strong> Capable of expressing multiple viral components<br>
                        • <strong>Reproducibility:</strong> Standardised, controllable system</p>
                    </div>
                </div>

                <div class="content_section">
                    <h3>Molecular Cloning Strategy</h3>
                    <p>Chimeras were generated using circular polymerase extension reaction (CPER).</p>
                    <ul>
                        <li><strong>CPER:</strong> Due to the limitations of traditional cloning methods, bacterium-free methods such as circular polymerase extension reaction (CPER) have been developed. CPER involves amplifying viral cDNA fragments and a linker fragment containing a CMV promoter which are assembled into circular DNA and transfected into cells to recover infectious virus. This is advantageous as it allows for the manipulation of viral genome sequences via standard PCR strategies enabling rapid and reliable generation of recombinant infectious clones.</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Antigenic Characterisation Methods</h3>
                    <p>Multiple complementary techniques were employed:</p>
                    
                    <h4 style="margin-top: 1.5rem;">Enzyme-Linked Immunosorbent Assay (ELISA)</h4>
                    <ul>
                        <li>Detection of viral antigens using strain-specific and cross-reactive antibodies</li>
                        <li>Quantification of protein expression levels</li>
                        <li>Assessment of conformational epitopes</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">SDS-PAGE</h4>
                    <ul>
                        <li>Virus concentration was estimated using BSA standards.</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Neutralisation Assays</h4>
                    <ul>
                        <li>Testing against reference sera from vaccinated/infected individuals</li>
                        <li>Assessment of cross-reactivity between constructs</li>
                        <li>Evaluation of neutralising antibody potential</li>
                    </ul>
                </div>

            </div>
        </div>
    </section>

    <!-- Results Section -->
    <section class="detail_section" id="results-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Results</h2>

                <div class="content_section">
                    <h3>Antigenic Properties</h3>
                    
                    <h4 style="margin-top: 1.5rem;">ELISA Results</h4>
                    <p>Comparative antigenicity assessment revealed:</p>
                    <ul>
                        <li><strong>Pathogenic Constructs:</strong> High reactivity with strain-specific polyclonal antisera (OD₄₅₀ > 2.0)</li>
                        <li><strong>Chimeric Constructs:</strong> Reduced reactivity with parent strain antisera (OD₄₅₀ 0.8-1.5), indicating antigenic modification</li>
                        <li><strong>Cross-Reactivity:</strong> Modest cross-reactivity between chimeric constructs (≈40-60% of homologous signal)</li>
                        <li><strong>Reproducibility:</strong> Low inter-assay variability (CV < 10%) across independent experiments</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Summary of Key Findings</h3>
                    <ul>
                        <li>✓ Successfully generated and propagated all viral constructs in insect cells</li>
                        <li>✓ Confirmed proper protein expression and maturation for both construct types</li>
                        <li>✓ Demonstrated distinct antigenic signatures between pathogenic and chimeric variants</li>
                        <li>✓ Established insect-specific platform as viable for alphavirus research</li>
                        <li>✓ Identified chimeric constructs as potential vaccine leads with safety enhancements</li>
                    </ul>
                </div>

            </div>
        </div>
    </section>

    <!-- Future Section -->
    <section class="detail_section" id="future-section">
        <div class="section_container">
            <div class="detail_content">
                <h2>Future Directions</h2>

                <div class="content_section">
                    <h3>Dissociation Constant (kd) Analysis</h3>
                    <p>While this project focused on antigenic characterisation, due to time limitations the project only focused on a limited panel of viruses, including: </p>
                    <ul>
                        <li>O'nyong'nyong Virus (ONNV) - closely related to Chikungunya</li>
                        <li>Mayaro Virus - emerging threat in South America</li>
                        <li>Sindbis Virus - model organism with clinical relevance</li>
                        <li>Semliki Forest Virus - well-characterised reference strain</li>
                    </ul>
                </div>

                <div class="content_section">
                    <h3>Applications</h3>

                    <h4 style="margin-top: 1.5rem;">Diagnostic Development</h4>
                    <ul>
                        <li>Recombinant antigens for serological testing</li>
                        <li>Reference reagents for quality control</li>
                        <li>Novel diagnostic platforms</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Antiviral Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                    <h4 style="margin-top: 1.5rem;">Vaccine Development</h4>
                    <ul>
                        <li>...</li>
                    </ul>

                </div>

                <div class="highlight_box">
                    <h4>Conclusion:</h4>
                    <p>This research establishes a critical foundation for understanding alphavirus antigenicity and vaccine development. The insect-specific platform offers a paradigm for safe, effective development of vaccines against dangerous pathogens, with immediate applications to alphavirus vaccines and broader potential for other emerging infectious diseases.</p>
                </div>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="footer">
        <div class="footer_container">
            <div class="footer_section footer_brand">
                <h3 class="footer_title">Alphavirus Research Project</h3>
                <p class="footer_subtext">Antigenic Characterisation | SCIE3121</p>
            </div>
            <div class="footer_section">
                <h4>Quick Links</h4>
                <ul class="footer_links">
                    <li><a href="#home">Poster</a></li>
                    <li><a href="#background-section">Background</a></li>
                    <li><a href="#methods-section">Methods</a></li>
                    <li><a href="#results-section">Results</a></li>
                    <li><a href="#future-section">Future Work</a></li>
                </ul>
            </div>
        </div>
        <div class="footer_bottom">
            © 2025 SCIE3121 Research Project. All Rights Reserved.
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>